

SARS-CoV-2 Detection in the Nasopharyngeal Swabs and Saliva of College Students using RT-qPCR and RT-LAMP

Authors:

D. A. Bikos^{a,b}, C. Hwang^b, K. A. Brileya^b, A. Parker^{b,d}, E. K. Loveday^{a,b}, M. Rodriguez^c, I. Thornton^{e,b}, T. LeFevre^{a,b}, J. N. Wilking^{a,b}, M. Dills, S. T. Walk^c, A. K. Adams^f, R. K. Plowright^c, A. B. Hoegh^d, J. R. Carter^g, J. Morrow^b, M. P. Taylor^c, D. E. Keil^f, M. W. Fields^{b,c*}, and C. B. Chang^{a,b*}

Affiliations:

^aDepartment of Chemical & Biological Engineering, Montana State University, Bozeman, MT 59717, United States

^bCenter for Biofilm Engineering, Montana State University, Bozeman, MT 59717, United States

^cDepartment of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, United States

^dDepartment of Mathematical Sciences, Montana State University, Bozeman, MT 59717, United States

^eDepartment of Mechanical & Industrial Engineering, Montana State University, Bozeman, MT 59717, United States

^fCenter for American Indian and Rural Health Equity (CAIRHE), Montana State University, Bozeman, MT 59717, United States

^gHealth & Human Development, Montana State University, Bozeman, MT 59717, United States

*Co-corresponding authors:

Connie B. Chang

Department of Chemical and Biological Engineering
Center for Biofilm Engineering
Montana State University

Matthew W. Fields

Department of Microbiology and Immunology
Center for Biofilm Engineering
Montana State University

Abstract

Background

Diagnostic testing can identify outbreaks and inform preventive strategies for slowing the spread of SARS-CoV-2, the virus that causes Covid-19. The “gold standard” method for detection of SARS-CoV-2 is reverse transcription quantitative polymerase chain reaction (RT-qPCR) performed on samples collected using nasopharyngeal (NP) swabs. While NP RT-qPCR achieves high sensitivity, it requires trained personnel to administer and suffers from lengthy time-to-result. Instead, rapid saliva-based reverse transcription loop-mediated amplification (RT-LAMP) screening methods may offer advantages in sample collection and speed.

Methods

Regardless of symptomatic presentation, a total of 233 individuals were tested for SARS-CoV-2 using NP RT-qPCR, alongside saliva-based RT-qPCR (SalivirDetect) and RT-LAMP (SLAMP), a simple and rapid fluorometric RT-LAMP assay performed directly on heat-inactivated saliva without any additional treatments or RNA extraction. SLAMP is conducted in triplicate and takes 45 min. Samples found negative using both saliva-based methods but positive under CDC NP RT-qPCR above the saliva method LoD were excluded from evaluation, suggesting significant differences in viral titer between sampling sites. Individuals who consumed potential inhibitors in the form of food, drink, and oral health products within 30 min of sampling were identified using a self-reported questionnaire.

Results

Of the 233 NP RT-qPCR tests, 58 were positive and 175 were negative. Comparatively, SLAMP resulted in 95% sensitivity and 98% specificity and SalivirDetect 97% sensitivity and 98% specificity. Prior consumption had no measurable effect on test outcomes, except for drinking, which lowered Ct values in saliva.

Conclusions

SLAMP requires less technician and instrument time than CDC-approved NP RT-qPCR and demonstrates that saliva-based RT-LAMP can enable frequent and rapid identification of pre-symptomatic and asymptomatic SARS-CoV-2 infections with high sensitivity and specificity.

56 **Introduction**

57 The SARS-CoV-2 virus¹ emerged in late 2019, rapidly developing into a worldwide pandemic still
58 posing a persistent threat to public health, economics, and quality of life. While real-world vaccine
59 efficacy continues to be evaluated², uncertainties over variant escape³, vaccine availability⁴, and
60 duration of immunity⁵ suggest that testing will continue to play an indispensable role in managing
61 the disease into the future. Viral spread can be controlled by deploying diagnostic tests that rapidly
62 identify infected individuals for quarantine and contact tracing. Rapid and frequent SARS-CoV-2
63 testing is needed to identify new outbreaks as the world struggles to lift lockdowns⁶ and reopen
64 schools for in-person instruction in Fall 2021⁷.

65
66 The “gold standard” method for detecting SARS-CoV-2 has been reverse transcription
67 quantitative polymerase chain reaction (RT-qPCR) performed on samples collected using
68 nasopharyngeal (NP) swabs⁸. However, RT-qPCR testing requires significant reagent
69 consumption, specialized equipment, trained operators, and several hours to perform. Collection
70 of NP swab samples is invasive and must be performed by trained medical personnel. Performing
71 surveillance at scale calls for innovative testing strategies that are inexpensive, minimize reagent
72 consumption, decrease assay time-to-result, and avoid restrictions in available personnel^{9,10}.

73
74 One such alternative to RT-qPCR is reverse transcriptase loop-mediated isothermal amplification
75 (RT-LAMP), an isothermal technique for the amplification of RNA¹¹. RT-LAMP simplifies SARS-
76 CoV-2 testing by eliminating the long assay times and technical barriers such as the electronically
77 controlled thermal cycling at high temperatures required by PCR-based methods¹²⁻¹⁷. RT-LAMP
78 is substantially faster than RT-qPCR, and when performed on saliva samples¹⁸, eliminates the
79 need for specialized swabs and operators while assuaging the public reluctance to testing, largely
80 brought on by invasive NP swabs¹⁹. The RT-LAMP assay is usually completed within 45 min to
81 confirm a negative, while some exceptionally high viral loads become detectable at ≈ 10 min²⁰.

82
83 Here, we report the findings of a multi-day pilot study to evaluate saliva-based SARS-CoV-2
84 detection using RT-qPCR and RT-LAMP methods compared alongside to Centers for Disease
85 Control and Prevention (CDC)-approved NP RT-qPCR testing at Montana State University (MSU)
86 during mid-November 2020, a time when Covid-19 cases reached county-wide highs (Figure S1).
87 We present the results of SLAMP, a rapid fluorometric RT-LAMP assay performed directly on
88 saliva without chemical extraction steps. Additionally, we compare SLAMP to SalivirDetect²¹, a
89 direct saliva-to-RT-qPCR assay and both saliva tests are compared to CDC-approved RT-qPCR
90 performed on samples swabbed from the nasopharynx. Each participant was provided a self-
91 reported survey identifying samples collected within 30 min of consuming food, drink, or oral
92 hygiene products to determine the extent to which saliva test results might be affected.

93

94 **Methods**

95

96 **Participants**

97 Samples were collected from 233 participants who visited the on-campus CDC-approved RT-
98 qPCR testing site provided for persons exhibiting Covid-19 symptoms or who suspected recent
99 contact with SARS-CoV-2-positive individuals. We directly compared samples from two sources
100 on the body of each participant, NP swabs, tested using CDC-approved RT-qPCR, and saliva,
101 tested using SLAMP and SalivirDetect. All individuals tested signed a consent form before
102 participating in this study (Supplementary Information – Consent Form).

103

104

105

106

107 **Self-Reported Questionnaire**

108 Participants were provided with a self-reported questionnaire (Supplementary Information -
109 Questionnaire) that collected demographic information including age, gender, race, and ethnicity.
110 Additionally, subjects were asked to confirm whether they were currently symptomatic or
111 asymptomatic and whether they had recent contact with infected individuals. Finally, subjects
112 were asked to disclose if they had, in the last 30 min, consumed food or liquid, used mouthwash,
113 gum or lozenges, smoked, vaporized or chewed tobacco, or brushed their teeth.

114 **Sample Collection**

115 All sampling occurred at an outdoor parking lot in drive-through format while participants remained
116 inside automobiles as an additional precaution against viral transmission. Individuals who
117 expressed interest in participating in our pilot study were administered NP swabs by trained staff
118 before donating an additional saliva sample as outlined by the university IRB (Supplementary
119 Information – IRB).

120 **Viral Inactivation - NP Swab**

121 NP swabs were heat-inactivated by diluting collection buffer 1:2 with molecular biology grade H₂O
122 (50 µL buffer: 50 µL H₂O) and assigned a location on a 96-well PCR plate. Plates were covered
123 with sealing foil and heated to 95 °C for 5 min in a standard thermocycler before being cooled to
124 4 °C until ready to test.

125 **Viral Inactivation - Saliva**

126 In the case of saliva collection, participants were given a 3D-printed accessory caddy
127 (Supplementary Methods, Figure S2) containing a 30-mL polypropylene medicine cup (MedPride
128 97205), a generic 1-mL transfer pipet, and a screw cap tube (VWR 16466-040). Saliva was
129 expressed into the medicine cup (Figure S3i) before using the pipet to transfer ≈1.0 mL into the
130 screw-cap tube (Figure S3ii). Tubes were indexed with heat- and water-resistant adhesive labels
131 (Electronic Imaging Materials, Inc. 667) prepared via barcode printer (TSC MB340T). Samples
132 were inactivated using a heat block (Labnet AccuBlock) set to 95 °C for 15 min (Figure S3iii)
133 simultaneously during which time ribonucleases were denatured and virions lysed. While not
134 strictly necessary, samples were removed from heat treatment and left at room temperature for
135 20 min to allow debris in the saliva to settle for easier pipetting. Barcodes were entered into
136 records using a handheld scanner (Motorola Symbol LS2208-SR20007R-NA).

137 **CDC-approved RT-qPCR from NP Swab**

138 Next, 10 µL of diluted, heat-inactivated²² sample material was mixed with 15 µL of each 1-step
139 PCR master mix consisting of: 1.) 1.5 µL each N1 and N2 primer probe set, 5 µL Quantabio
140 Ultraplex 1-Step Toughmix (4×), and 7 µL H₂O per reaction; 2.) 1.5 µL human RNase P reaction
141 primer probe mix, 5 µL Quantabio Ultraplex 1-Step Toughmix (4×), and 8.5 µL H₂O per reaction.
142 Real-time PCR thermocycling was performed per CDC guidelines²³. Each sample was screened
143 in a combined N1, N2 reaction with an internal control human RNase P reaction (Supplementary
144 Methods). Samples with no detectable fluorescence for either assay and those with SARS-CoV-
145 2 target fluorescence between 39.5 and 45 cycle thresholds (Ct) were re-tested using a validated
146 RNA purification kit (Promega Maxwell RSC Viral Total Nucleic Acid Multi-Pack Kit, ASB1330).
147 RNA-purified samples were assayed under the same conditions, but with 5 µL of purified sample
148 added to each reaction for 20 µL total reaction volume. No replicates were performed.

149 **SalivirDetect - RT-qPCR in saliva**

150 SLAMP was compared to the saliva-based RT-qPCR assay SalivirDetect with FDA Emergency
151 Use Authorization (EUA) application number EUA202615, submitted August 25, 2020 and
152 developed by Drs. Phillip Buckhaults and Carolyn Banister (University of South Carolina).

158 SalivirDetect, like SLAMP, uses heating at 95 °C to process saliva without inactivation buffers or
159 additives. SalivirDetect was conducted in the InHealth Life Sciences CLIA/CAP laboratory led by
160 Dr. Deborah Keil (MSU). Briefly, ≈5 mL of saliva was collected in a 50-mL centrifuge tube. The
161 tube was placed in a 95 °C oven (Fisherbrand Isotemp General Purpose Heating and Drying
162 Oven) for 45 min, then allowed to sit at room temperature to cool. Two 5-μL aliquots of the saliva
163 were transferred to two wells in a 96-well plate containing Luna Kit RT-qPCR reagents (E3600,
164 New England Biolabs), one well containing N1 primers and the second well containing human
165 RNase P primers from the United States CDC Real-Time Reverse Transcription PCR Panel for
166 SARS-CoV-2 detection (Supplementary Methods). Samples were run on a CFX Opus 96 Real-
167 Time qPCR instrument (Bio-Rad, cat no. 12011319). Only a single test per sample was performed
168 with no replicates.

169

170 **SLAMP - RT-LAMP in saliva**

171 RT-LAMP reactions were set up as described by protocol E1700 (New England Biolabs) at 25 μL
172 final reaction volume with the following modified formulation: 12.5 μL WarmStart 2X Master Mix
173 (E1700L, New England Biolabs) 0.175 μL of dUTP (N0459S, New England Biolabs), 0.5 μL of
174 UDG (M0372L, New England Biolabs), 2.5 μL of duplex NE primer mix (Supplementary Methods),
175 0.5 μL of 25-μM SYTO-9 (S34854, Invitrogen), 0.25 μL of 25-μL ROX reference dye (61110,
176 Lumiprobe), 2.5 μL of 400-mM molecular biology grade guanidine HCl (GuHCl) (J65661, Alfa
177 Aesar), 1.075 μL of nuclease-free water (B1500L, New England Biolabs), and 5 μL of heat-
178 inactivated saliva sample. Controls were run on each 96-well plate, including SARS-CoV-2-
179 negative heat-inactivated saliva as a no-template control (NTC), human beta-actin (ACTB) as a
180 positive internal control, and three positive test controls of 5×10^4 , 5×10^2 , and 5×10^0 copies/μL
181 synthetic SARS-CoV-2 RNA (NIST, RGTM 10169 Fragment 1) (Supplementary Methods).
182 Positive test control dilutions were made using heat-inactivated SARS-CoV-2-negative saliva. All
183 SLAMP reactions were prepared in 96-well qPCR plates (Applied Biosystems, 4483485) sealed
184 using an ALPS 50V manual heat sealer (Thermo Scientific) with Clear Seal Diamond films (AB-
185 0812, Thermo Scientific). Reactions were performed at 65 °C (1.6 °C/s ramp) on a QuantStudio
186 3 Real-Time PCR System (Applied Biosystems) (Figure S3iv) for 45 min. Fluorescence
187 measurements for SYTO-9 and ROX channels were recorded every 1 min. SARS-CoV-2 may be
188 present in highly variable amounts within the nasopharynx and the saliva²⁴. To avoid invalid test
189 samples where RNA was present only in the NP swab, only NP RT-qPCR-positive samples that
190 also tested positive under at least one of the two saliva methods were included in this study. Any
191 time-to-positive $T_p > 40$ min was considered negative. See Supplementary Methods for reaction
192 curve-fitting procedure and SLAMP formulation optimization. Each saliva sample was run in
193 triplicate.

194

195 **Statistical Analysis**

196 Statistical bootstrapping²⁵ methods can predict how the normally triplicate SLAMP sensitivity and
197 specificity may change when performed only in duplicates or single tests. Using our (triplicate, 45
198 min) SLAMP test results, 1,000 random bootstrap samples were used to predict sensitivity with
199 respect to CDC-approved NP RT-qPCR at 95% confidence intervals when only 1 or 2 SLAMP
200 reactions are performed per sample. In addition, we model the outcomes of SLAMP testing under
201 hypothetical disease prevalence scenarios. Based upon the experimental sensitivity of SLAMP in
202 triplicate and the bootstrap-predicted sensitivities of duplicate and single SLAMP tests, we
203 determine the total number of detectable positive individuals based on a daily testing capacity of
204 six 384-well plates, reserving 10 wells for controls when performed in triplicate, duplicate, or single
205 tests. Specificity is assumed to remain constant.

206


207 All t-tests are reported as p values. Pearson correlation coefficients are reported as r values.

208
209
210
211
212
213
214
215
216
217
218

Results

Comparing testing methods: SLAMP, SalivirDetect, and NP RT-qPCR.

We compare samples from two matrices, NP swab and saliva, across three different testing methods, SLAMP, SalivirDetect, and the "gold standard" CDC-approved NP RT-qPCR, the latter performed using NP swab while saliva, shown to provide sufficient viral RNA for detection^{26,27}, was used for both SLAMP and SalivirDetect. Both SalivirDetect and CDC-approved NP RT-qPCR are PCR-based while SLAMP uses isothermal LAMP amplification. SLAMP was performed in triplicate while SalivirDetect and NP RT-qPCR tests were performed only once (Figure 1).



219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235

Figure 1. Sample collection and testing.

Demographics

Participant ages ranged from 17 to 63 with a median age of 20. Males made up 47% and females 53%. Participants were comprised of 94% white and 6% other races including Asian and mixed-race individuals of American Indian, Alaskan Native, Native Hawaiian or Pacific Islander, and African American descent. Ethnically, 9 individuals self-reported as Hispanic or Latino, 207 as not Hispanic or Latino, and 17 chose not to respond (Table 1).

Clinical presentation

Participants self-reported their illness presentation as either symptomatic or asymptomatic and indicated whether they had knowledge of recent exposure to a confirmed Covid-19-positive individual. A majority 74% of study participants self-reported as symptomatic among whom 46% indicated knowledge of recent exposure. Among the 29% asymptomatic, 6% were unaware of exposure, the remaining 94% sought testing after learning of SARS-CoV-2 exposure (Table 1).

236
237
238
239
240
241
242
243
244
245
246
247
248

Potential saliva contamination

Testing was conducted on a first come, first served basis without appointments. Therefore, instructions to abstain from food, drink, or oral hygiene products before donating saliva could not be provided to participants ahead of time. To determine the extent to which saliva may have been affected, the questionnaire asked participants whether they had eaten food or consumed drinks within 30 min of sampling. In addition, other consumables or oral hygiene products that may have persisted in saliva were also included, namely mouthwash, gum/lozenge, tobacco (whether smoked, vaporized, or chewed), and toothpaste from brushing teeth. Many participants had consumed multiple items. In order to make quantitative comparisons between saliva sample Ct values, we report the consumption survey results for individuals who testing positive using SalivirDetect (Table 1).

Table 1. Self-reported Demographic Information and Clinical Presentation.	
Characteristic	Participants (N = 233)
Sex - no.	
Male	109
Female	124
Median Age (IQR)* – yr	20 (19-22)†
Race – no.	
White	220
Asian	1
Mixed race	11
Not provided	1
Ethnicity – no.	
Hispanic or Latino	9
Not Hispanic or Latino	207
Not provided	17
Clinical Presentation – no.	
Symptomatic (known exposure)	76
Symptomatic (no known exposure)	88
Asymptomatic (known exposure)	64
Asymptomatic (no known exposure)	4
Not provided	1
Consumption within 30 min of Saliva Sampling†† – no.	
Only Food	4
Only Drink	23
Both Food and Drink	10
Neither Food nor Drink	21
Mouthwash†††	
Yes	5
No	52
Gum or Lozenge†††	
Yes	6
No	52
Tobacco††† (Smoke, Vape, or Chew)	
Yes	7
No	51

Brushed Teeth^{†††}	
Yes	31
No	27

249 * Interquartile range.
 250 † N = 223 (10 non-respondent).
 251 †† Tested positive using SalivirDetect.
 252 ††† Multiple selections possible.


253 **Testing outcomes - performance of the three methods**

254 Performance metrics of saliva methods SalivirDetect and SLAMP were evaluated by comparing
 255 results to the "gold-standard" CDC-approved NP RT-qPCR method between 233 individuals
 256 tested using all three methods. We report the true positive (TP), true negative (TN), false positive
 257 (FP), and false negative (FN) counts along with the true positive rate (TPR) and true negative rate
 258 (TNR), also called sensitivity and specificity, respectively (Table 2). The sensitivity/specificity (in
 259 %) of SalivirDetect and SLAMP methods were 97/98 and 95/98, respectively. Based on NP RT-
 260 qPCR, 58 positive and 175 negative individuals were identified resulting in a disease prevalence
 261 of 25%.
 262
 263

Table 2. Test Outcomes and Performance Metrics.	
Method and Category	
NP RT-qPCR (CDC-approved "gold standard")	
Diseased	58
Non-diseased	175
Saliva RT-qPCR (SalivirDetect)	
True Positives (TP)	56
True Negatives (TN)	220
False Positives (FP)	3
False Negatives (FN)	2
Sensitivity (%)	97
Specificity (%)	98
Saliva RT-LAMP (SLAMP)	
True Positives (TP)	55
True Negatives (TN)	172
False Positives (FP)	3
False Negatives (FN)	3
Sensitivity (%)	95
Specificity (%)	98

264 **Comparing positive samples - two sample matrices and three testing methods**

265 The 58 samples found positive under CDC-approved NP RT-qPCR are placed in order of
 266 increasing Ct value (decreasing effective SARS-CoV-2 genome concentration or viral titer) and
 267 compared to Ct values under SalivirDetect (Figure 2A) and Tp values using SLAMP (Figure 2B).
 268 Samples positive under saliva-based tests are compared in order of increasing SalivirDetect Ct
 269 value (Figure 2C) and increasing SLAMP Tp value (Figure 2D). False negatives are shown as
 270 missing bars and indicated by black arrows.
 271
 272



273
274 **Figure 2. Positive sample results compared between three tests.** Ct values of N=58 positive
275 NP RT-qPCR and SalivirDetect samples in order of increasing CDC-approved NP RT-qPCR Ct
276 value (Panel A). Ct values of N=58 positive CDC-approved NP RT-qPCR and Tp values of
277 SLAMP samples in order of increasing CDC-approved NP RT-qPCR Ct value (Panel B). Ct values
278 of N=59 positive SalivirDetect and Tp values of SLAMP samples presented in order of increasing
279 SalivirDetect Ct value. Dashed line indicates 95% confidence interval SLAMP limit of detection
280 (Panel C). Tp and Ct values of N=58 positive SLAMP and SalivirDetect tests, respectively,
281 in order of increasing SLAMP Tp value (Panel D). Black arrows indicate undetected samples. Error
282 bars represent one standard deviation.

283

284

Test outcomes and viral titers by age

285 A total of 223 participants provided age information and among these 56 were confirmed positive
286 for SARS-CoV-2 using CDC-approved NP RT-qPCR. A histogram of these ages shows the
287 positive results (gray) superimposed over the negative results (white), including one outlier age
288 of 63 (Figure 3A). The most common age to be positive and negative is equal to the mode of 19
289 years old. Not surprisingly, the positive and negative distributions are similar ($p = 0.407$). Average
290 Ct values as a function of age also indicate no trend in positivity as a function of this narrow age
291 window (Figure 3A, inset).

292

293

Self-reported clinical presentations and test results

294 Participants were classified into four categories defined by their questionnaire responses:
295 symptomatic exposed, symptomatic unexposed, asymptomatic exposed, and asymptomatic
296 unexposed. Samples in each self-reported category were confirmed negative or positive based
297 on CDC-approved NP RT-qPCR and positive individuals were assigned a Ct value. The 2nd
298 largest category was symptomatic exposed numbering 76 individuals. Among these, only 20
299 participants were confirmed SARS-CoV-2-positive, around 26%. Symptomatic unexposed, the
300 largest of all four categories, was comprised of 88 individuals from which 27 were confirmed
301 positive, around 31%. The asymptomatic and exposed respondents numbered 64, of which only

302 9 tested positive, a total of only 14%. The smallest category was comprised of four participants
303 who were asymptomatic and unexposed. Of these, half tested positive. Histograms of Ct values
304 among the positive results with inset pie charts representing the fraction of confirmed SARS-CoV-
305 2 positives (blue) among the negatives (white) for each category are shown in Figure 3B.

306

307 **Consumption of potential inhibitors – effect on SalivirDetect Ct values**

308 Distributions of SalivirDetect Ct values among individuals who had or had not consumed each
309 potential inhibitor are shown in Figure 3C. Among those engaging in eating and drinking, only the
310 Ct values of those who drank were statistically distinct compared to those who did not ($p = 0.041$).
311 No other items consumed resulted in statistically significant differences in the Ct distributions of
312 those populations. The p-values for comparisons of all other sets were >0.05 .

313

314 **Site comparison: Nasopharynx versus saliva**

315 CDC-approved NP RT-qPCR and SalivirDetect provide Ct results that can be quantitatively
316 compared between NP swabs and saliva (Figure 3D). We compare the viral titers of 56 individuals
317 who tested positive under both methods. Viral titer has been shown to vary between these sites
318 ²⁸. Among samples with lower NP swab Ct values, assumed to correspond to a higher viral titer,
319 saliva samples Ct values were higher, implying a lower viral titer than in the nasopharynx.
320 However, when NP swab Ct values imply lower viral titers, Ct values in saliva were significantly
321 lower, implying a difference in viral concentration between nasopharynx and oral mucosa (saliva)
322 of possibly four orders of magnitude. Furthermore, there is a definite jump in values for the NP
323 swab results from Ct=30-34, after which saliva Ct values are all lower than NP swab (Figure 3D,
324 left). A correlation plot of NP vs. saliva Ct values reveals that the results have only a weak positive
325 correlation ($r = 0.310$).

326

327 **Statistical predictions for SLAMP tests at triplicate, duplicate, or as a single replicate**


328 For each number of test replicates, sensitivity increases as a function of SLAMP assay duration
329 (Figure 3E). As reported here, 45-min SLAMP with 3 replicates produced a sensitivity of 95%
330 (95% CI: [87.9%, 100%]) as compared to the CDC-approved NP RT-qPCR standard results.
331 Bootstrapping predicted a 90% sensitivity (95% CI: [82.8%, 96.6%]) for SLAMP with two
332 replicates, and a 82% sensitivity (95% CI: [70.7%, 89.7%]) for SLAMP with a single replicate after
333 the full assay time of 45 min had passed. For example, half of all positives in a test population
334 would be detected by a single SLAMP test after 19.0 min (95% CI: [17.7 min, 21.5 min]), duplicate
335 tests after 18.4 min (95% CI: [17.4 min, 19.3 min]), and triplicate tests after 17.7 min (95% CI:
336 [16.9 min, 18.8 min]).

337

338 Based upon an estimated testing capacity of six 384-well plates per day (see Methods), we
339 compare three scenarios of running samples with a single replicate, duplicate, and triplicate
340 (Figure 3F). For these scenarios, we use the sensitivity values from Figure 3E. The specificity is
341 assumed to be a constant 98% for all scenarios and there are 10 wells in each plate reserved for
342 controls. Given the fixed constraint on the number of tests ($\approx 384 \times 6$), screening a larger number
343 of individuals can identify more positive cases. For example, at a disease prevalence of 10%,
344 triplicate SLAMP would identify approximately 10.0 true positives (TP) at the cost of 2.4 false
345 positives (FP) per 384-well plate with FPs equaling the number of TPs at a disease prevalence of
346 2.5%. For duplicate SLAMP, TP = 16.8, FP = 3.3, and TP = FP at a disease prevalence of 2.2%.
347 Finally, for single test SLAMP, TP = 35.4, FP = 6.9, and TP = FP at a disease prevalence of and
348 2.0%.

349

350



351
352
353
354
355
356
357

Figure 3. Study results and statistical predictions. Histogram of participant age distributions, $N=223$. Gray and white bars represent positive and negative participants, respectively, tested using CDC-approved NP RT-qPCR ($p = 0.407$). Inset: average Ct values of SARS-CoV-2-positive CDC-approved NP RT-qPCR tests as a function of participant age ($r = 0.00539$). Error bars represent one standard deviation (Panel A). Histograms of CDC-approved NP RT-qPCR Ct

358 values of SARS-CoV-2-positive participants self-reported as (from left-to-right) symptomatic
359 exposed (N=76), symptomatic unexposed (N=88), asymptomatic exposed (N=64), and
360 asymptomatic unexposed (N=4). Insets: fraction of positive tests (blue) and negative tests (white)
361 within each category (Panel B). Box-and-whisker plots of SalivirDetect Ct values for individuals
362 who both ate and drank (N=10), ate only (N=4), drank only (N=23), and did neither (N=21) (left
363 panel) in addition to having used mouthwash (N=5), no mouthwash (N=52), gum/lozenge (N=6),
364 no gum/lozenge (N=52), tobacco (N=7), no tobacco (N=51), brushing (N=31), and no brushing
365 (N=27) (right panel) within 30 min of saliva sampling. Box-and-whisker plots define minimum, first
366 quartile, median, third quartile, and maximum values (Panel C). Comparison between collection
367 sites on the body. The Ct values of 56 positive CDC-approved NP RT-qPCR samples are plotted
368 in increasing order (closed black squares). Open blue circles represent the SalivirDetect Ct values
369 of the 56 corresponding saliva samples. Vertical lines connect NP and saliva values to guide the
370 eye (left subplot). Cluster plot of Ct values of CDC-approved NP RT-qPCR vs. SalivirDetect.
371 Dashed line indicates perfect correlation ($r = 0.310$) (right subplot) (Panel D). Bootstrap-predicted
372 percentage of total positive individuals detected within a testing population as a function of
373 SLAMP assay time for triplicate, duplicate or single replicate test conditions. Dashed lines indicate
374 the mean. Solid lines indicate 95% bootstrap confidence intervals (Panel E). Total number of
375 positive cases identified using SLAMP per 384-well plate as a function of disease prevalence for
376 three, two, and single replicate tests. True positives (blue) and false positives (red) are generated
377 for disease prevalence rates between 0 and 10% for single replicates, duplicates, and triplicates
378 based on a daily capacity of six 384-well plates, reserving 10 wells for controls (Panel F).

379

380 **Safety**

381 Testing site volunteers were equipped with powered air-purifying respirators (PAPRs) during
382 sample collection. Samples were transported in hard-sided coolers with biohazard labels. Contact
383 surfaces were frequently disinfected using 70% ethanol solutions. All samples should be assumed
384 to contain infectious SARS-CoV-2 virus and must be rendered safe through viral inactivation²⁹
385 before testing. HEPA air purifiers (Medify Air MA-25) were used in the testing laboratory. All
386 samples were heat inactivated before storage. See Supplementary Methods and Figure S4 for
387 validation of viral heat-inactivation procedure.

388

389 **Discussion**

390

391 The demographics of this study (Table 1) reflect those of many universities throughout the US.
392 The median age of study participants was 20 years, and 94% of participants were ages 18-24.
393 This study was comprised of 53% females and 47% males. By comparison, the 2020 MSU student
394 population was comprised of 48% females, 51% males, and <1% other³⁰. This difference is in
395 agreement with observations that suggest women seek Covid-19 testing, more than males^{31,32}
396 and are more likely to take covid precautions seriously³³. In terms of race, this study was
397 comprised of 94.4% white and 5.6% non-white participants. By comparison, the 2020 MSU
398 student population was comprised of 84% white and 16% non-white³⁰. This difference of 10%
399 may reflect differences in likelihood to seek Covid-19 testing³⁴. The average US university in Fall
400 2020 was around 49% white³⁵, more racially diverse than represented within our study.
401 Nevertheless, we have no reason to doubt that SLAMP testing would be successfully employed
402 among the student populations of other universities.

403

404 RT-LAMP (SLAMP) and RT-qPCR (SalivirDetect) Covid-19 tests performed on the saliva of 233
405 adults³⁶ yielded 98% specificity for both and 95% and 97% sensitivity, respectively, sensitivities
406 comparable to SalivaDirect³⁷.

407

408 Surveying revealed that while 70% of pilot study participants identified as symptomatic, only 29%
409 of these tested positive for SARS-CoV-2 (Table 2). Overall, the prevalence of Covid-19 disease
410 was 25%, a number that coincides with incidence levels of 9-31% across the US, as estimated in
411 the months prior to our study³⁸. Only 5% were asymptomatic positives compared to the estimates
412 of around 40% asymptomatic among the general population³⁹ which is likely due to testing being
413 reserved only for those with symptoms or recent exposures. We expect a random screening of
414 the population would likely have produced a higher asymptomatic positive rate, given estimates
415 ranging from 40-45% asymptomatic positive rate⁴⁰.

416
417 While interference from food, drink, oral care products, and tobacco are a concern for saliva
418 diagnostics⁴¹, we observed no significant differences in Ct distributions of SalivirDetect positive
419 results who had or had not consumed food, oral care products, or tobacco within 30 min of saliva
420 sampling. Interestingly, those who had consumed drink produced significantly lower Ct values (p
421 = 0.407) than those who had not (Figure 3C). This suggests that hydrating the mouth before
422 expressing saliva may stimulate its production, at least temporarily⁴², and contribute to the supply
423 of greater viral genome from the oral mucosa⁴³.

424
425 Viral load in saliva is consistently higher than NP swab. Strikingly, positive samples with the
426 highest CDC NP RT-qPCR Ct values >30 are surprisingly lower than in saliva, representing a
427 higher concentration of virus in the saliva of the oral mucosa under conditions of low titer in the
428 nasopharynx (Figure 3D). In fact, all saliva samples had $Ct \leq 35$, and the 9 individuals with the
429 lowest NP swab virus concentrations ($Ct > 35$) had significantly lower Ct for the corresponding
430 saliva sample test. SARS-CoV-2 infections have exhibited high tissue compartmentalization and
431 data suggests viral titers may peak earlier in saliva than in NP swabs²⁴.

432
433 While the SLAMP test has higher sensitivity when run in triplicate, running a single test can be
434 advantageous. Given finite resources, driven by cost or supply availability, a single test on an
435 individual can identify a substantially larger amount of infected, and infectious, individuals. We
436 modeled the sensitivities and specificities of double and single tests from the triplicate SLAMP
437 test data. Figure 3F shows the total number of positive individuals that can be identified by running
438 a single 384-well plate in either triplicate, duplicate, or with a single test. Triplicate and duplicate
439 have higher sensitivity, with 95% and 90% respectively, compared to that of a single test at 82%;
440 however, running a single test allows more individuals to be tested.

441
442 It should be noted that specificity is assumed constant across the three SLAMP replicates (Figure
443 3F, red lines). Therefore, running more tests, with a lower specificity can also lead to more false
444 positives that may require confirmatory testing. Recent work¹⁰ has demonstrated that more
445 frequent testing with LAMP was more effective at reducing epidemic size than deploying more
446 sensitive tests. Our analyses regarding sensitivity predict that running more samples with single
447 replicates will lead to more false negatives, but ideally a high frequency testing strategy would
448 catch those other cases¹⁰. Nonetheless, the data suggest that the SLAMP assay run in triplicate
449 per individual could perform at the level of a clinical diagnostic, while when run as a single
450 replicate could be used as a broad screening tool to identify unknown positives.

451
452 These results represent the intersection of self-reported demographics, disease presentation, and
453 potential interferences. Our study size of $N=233$ with 58 diseased can be statistically interpreted
454 with acceptable accuracy¹⁰. However, the sample number in the case of some interferences is
455 low and limits statistical power.

456
457 SARS-CoV-2 testing that is rapid, simple, and requires no specially trained medical personnel is
458 indispensable when large numbers of individuals must be frequently screened while remaining

459 economical. In this study, we have compared three testing methods, NP RT-qPCR, SalivirDirect,
460 and SLAMP. All three methods use simple heat to both inactivate and extract, which avoids costly
461 reagents and potential supply bottlenecks. We conducted a comparison of these tests between
462 233 individuals from the MSU symptomatic testing site in mid-November of 2020, at the height of
463 the largest county-wide wave of Covid-19 cases, where we detected a disease prevalence of
464 25%. Compared to the "gold standard" NP RT-qPCR results, SalivirDetect and SLAMP achieved
465 97% and 95% sensitivity and 98% and 98% specificity, respectively. We have demonstrated our
466 SLAMP method offers a faster and simpler, while still comparatively sensitive, alternative to NP
467 swabs and RT-qPCR methods for routine sampling, particularly of a college population.
468

469
470
471 Supported by the State of Montana through the Coronavirus Aid, Relief and Economic Security
472 Act (CARES) Act.
473

474 Connie B. Chang and James N. Wilking are co-founders of ULTSafety, Inc. which has licensed
475 technology from Montana State University and Harvard University relating to this publication.
476

477 We thank Nathan Tanner at New England Biolabs, Kathryn Kundrod in the Richards-Kortum
478 group (Rice University), Paul Hergenrother (UIUC), and the Global LAMP R&D Consortium led
479 by Christopher Mason (Weill Cornell Medicine) for helpful discussions. We thank MSU students
480 Kyle Hain, Shawna Pratt, Emily Walter, Matthew Fisher, and Jerrica Bursik for sample collection
481 and Donna Gollehon (MSU University Health Partners), Ryan Brickman (MSU Safety and Risk
482 Management), and Ryan Bartlett (MSU Office of Research Compliance) for their assistance
483 throughout the approval process and especially with sample site logistics. We thank the MSU
484 Center for American Indian and Rural Health Equity for the use of the Health Education and
485 Research Bus (HERB) at the sample collection site. HERB is a mobile laboratory and outreach
486 facility supported by an Institutional Development Award (IDeA) from the National Institute of
487 General Medical Sciences of the National Institutes of Health under grant
488 numbers P20GM104417 and P20GM103474.
489

490 **Author Affiliations**

491
492 From the Montana State University Department of Chemical & Biological Engineering (D.A.B.,
493 E.K.L., T.L., I.T., J.N.W., C.B.C.), Center for Biofilm Engineering (D.A.B., C.H., K.A.B., A.P.,
494 E.K.L., T.L., I.T., J.N.W., J.M., M.W.F., C.B.C.), Department of Microbiology & Immunology (M.R.,
495 S.T.W., R.K.B., M.P.T., D.E.K., M.W.F.), Department of Mathematical Sciences (A.P., A.B.H.),
496 Center for American Indian and Rural Health Equity (CAIRHE) (A.K.A.), and Health & Human
497 Development (J.R.C.).
498

499 Address reprint requests to co-corresponding authors Connie B. Chang, Ph.D. or Matthew W.
500 Fields, Ph.D. at the Department of Chemical and Biological Engineering or Department of
501 Microbiology and Immunology, respectively, Center for Biofilm Engineering, Montana State
502 University, 366 Barnard Hall, Bozeman, MT 59717, or at connie.chang@montana.edu or
503 matthew.fields@montana.edu, respectively.
504

505
506
507
508
509

510 References

- 511
- 512 1. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging
513 in China — Key Questions for Impact Assessment. *New England Journal of Medicine* 2020;382:692-4.
- 514 2. Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the elephant (not)
515 in the room. *Lancet Microbe* 2021.
- 516 3. Thompson RN, Hill EM, Gog JR. SARS-CoV-2 incidence and vaccine escape. *Lancet Infect Dis* 2021.
- 517 4. Castillo JC, Ahuja A, Athey S, et al. Market design to accelerate COVID-19 vaccine supply. *Science*
518 2021;371:1107-9.
- 519 5. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and
520 duration of immunity: a longitudinal study. *Lancet Microbe* 2021.
- 521 6. Kirby T. When should the UK lift its lockdown? *Lancet Respir Med* 2021;9:e44-e5.
- 522 7. Head JR, Andrejko KL, Cheng Q, et al. School closures reduced social mixing of children during
523 COVID-19 with implications for transmission risk and school reopening policies. *J R Soc Interface*
524 2021;18:20200970.
- 525 8. Guidance for Antigen Testing for SARS-CoV-2 for Healthcare Providers Testing Individuals in the
526 Community. (Accessed Updated Apr. 4, 2022, at [https://www.cdc.gov/coronavirus/2019-
527 ncov/lab/resources/antigen-tests-guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html).)
- 528 9. Mina MJ, Andersen KG. COVID-19 testing: One size does not fit all. 2021;371:126-7.
- 529 10. Rogers W, Ruiz-Aravena M, Hansen D, et al. High-frequency screening combined with diagnostic
530 testing for control of SARS-CoV-2 in high-density settings: an economic evaluation of resources allocation
531 for public health benefit. 2021:2021.03.04.21252949.
- 532 11. Mori Y, Notomi T. Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-
533 effective diagnostic method for infectious diseases. *J Infect Chemother* 2009;15:62-9.
- 534 12. Bhadra S, Maranhao AC, Paik I, Ellington AD. A One-enzyme RT-qPCR Assay for SARS-CoV-2, and
535 Procedures for Reagent Production. *Bio-protocol* 2021;11:e3898.
- 536 13. Buck MD, Poirier EZ, Cardoso A, et al. Standard operating procedures for SARS-CoV-2 detection
537 by a clinical diagnostic RT-LAMP assay. medRxiv 2020:2020.06.29.20142430.
- 538 14. Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the bottleneck to
539 widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. *RNA (New
540 York, NY)* 2020;26:771-83.
- 541 15. Kashir J, Yaqinuddin A. Loop mediated isothermal amplification (LAMP) assays as a rapid
542 diagnostic for COVID-19. *Medical Hypotheses* 2020;141:109786.
- 543 16. Yan C, Cui J, Huang L, et al. Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by
544 a reverse transcription loop-mediated isothermal amplification assay. *Clin Microbiol Infect* 2020;26:773-
545 9.
- 546 17. Lamb LE, Bartolone SN, Ward E, Chancellor MB. Rapid detection of novel coronavirus/Severe
547 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated
548 isothermal amplification. *PLoS One* 2020;15:e0234682.
- 549 18. Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. Saliva as a gold-standard sample for SARS-CoV-
550 2 detection. *The Lancet Respiratory Medicine*.
- 551 19. For Coronavirus Testing, the Nose May Not Always Be Best. *The New York Times* Jan. 14, 2022.
- 552 20. Thompson D, Lei Y. Mini review: Recent progress in RT-LAMP enabled COVID-19 detection.
553 *Sensors and actuators reports* 2020;2:100017-.
- 554 21. SalivirDetect. 2021, at
555 [https://sc.edu/study/colleges_schools/pharmacy/centers/diagnostic_genomics_covid_lab/salivir-
detect/index.php](https://sc.edu/study/colleges_schools/pharmacy/centers/diagnostic_genomics_covid_lab/salivir-
556 detect/index.php).)

- 557 22. A new process that can be used in place of the extraction method when materials for the current
558 method are limited. at <https://www.fda.gov/media/138931/download.>)
- 559 23. Diseases CDNDov. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
560 In: Prevention CfDca, ed. CDC-006-00019, Revision: 06 ed12/01/2020.
- 561 24. Ke R, Martinez PP, Smith RL, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals
562 substantial heterogeneity in infectiousness. *Nature Microbiology* 2022;7:640-52.
- 563 25. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall; 1993.
- 564 26. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. *J Infect*
565 2020;81:e48-e50.
- 566 27. Corstjens PLAM, Abrams WR, Malamud D. Saliva and viral infections. *Periodontol* 2000
567 2016;70:93-110.
- 568 28. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for
569 detection of SARS-CoV-2. *N Engl J Med* 2020;383:1283-6.
- 570 29. Adaway JE, Hawley JM, Lockhart SJ, Keevil BG. Heat Inactivation of Saliva Samples for the Analysis
571 of Cortisol and Cortisone during the COVID-19 Pandemic. *The Journal of Applied Laboratory Medicine*
572 2020;5:1413-6.
- 573 30. Quick Facts: 2020-2021. Montana State University, 2020-2021. 2021, at
574 <https://www.montana.edu/opa/facts/quickfactsarchive/quick21.html.>)
- 575 31. Lapointe-Shaw L, Rader B, Astley CM, et al. Web and phone-based COVID-19 syndromic
576 surveillance in Canada: A cross-sectional study. *PLOS ONE* 2020;15:e0239886.
- 577 32. Stall NM, Wu W, Lapointe-Shaw L, et al. Sex- and Age-Specific Differences in COVID-19 Testing,
578 Cases, and Outcomes: A Population-Wide Study in Ontario, Canada. 2020;68:2188-91.
- 579 33. Galasso V, Pons V, Profeta P, Becher M, Brouard S, Foucault M. Gender differences in COVID-19
580 attitudes and behavior: Panel evidence from eight countries. 2020;117:27285-91.
- 581 34. Jacobson M, Chang TY, Shah M, Pramanik R, Shah SB. Racial and Ethnic Disparities in SARS-CoV-2
582 Testing and COVID-19 Outcomes in a Medicaid Managed Care Cohort. *American journal of preventive*
583 *medicine* 2021;61:644-51.
- 584 35. Fast Facts. 2020. at <https://nces.ed.gov/fastfacts/display.asp?id=372.>)
- 585 36. Bujang MA, Adnan TH. Requirements for Minimum Sample Size for Sensitivity and Specificity
586 Analysis. *J Clin Diagn Res* 2016;10:YE01-YE6.
- 587 37. Vogels CBF, Watkins AE, Harden CA, et al. SalivaDirect: A simplified and flexible platform to
588 enhance SARS-CoV-2 testing capacity. *Med* 2021;2:263-80.e6.
- 589 38. Reese H, Iuliano AD, Patel NN, et al. Estimated Incidence of Coronavirus Disease 2019 (COVID-19)
590 Illness and Hospitalization—United States, February–September 2020. *Clinical Infectious Diseases*
591 2020;72:e1010-e7.
- 592 39. Ma Q, Liu J, Liu Q, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the
593 Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-
594 analysis. *JAMA Network Open* 2021;4:e2137257-e.
- 595 40. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection A Narrative Review. *Ann*
596 *Intern Med* 2020;173:362-+.
- 597 41. Kapoor P, Chowdhry A, Kharbanda OP, Popli DB, Gautam K, Saini V. Exploring salivary diagnostics
598 in COVID-19: a scoping review and research suggestions. *Bdj Open* 2021;7.
- 599 42. Jose A, Singh ML, Magnuson B, Farag A, Varghese R, Papas A. A randomized controlled study to
600 evaluate an experimental moisturizing mouthwash formulation in participants experiencing dry mouth
601 symptoms. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology* 2018;126:231-9.e5.
- 602 43. Benn AM, Thomson WM. Saliva: an overview. *The New Zealand dental journal* 2014;110:92-6.